Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Issue 2 (1st February 2023)

• Record Type: Journal Article
• Authors: Solana-Altabella, Antonio; Megías-Vericat, Juan Eduardo; Ballesta-López, Octavio; Martínez-Cuadrón, David; Montesinos, Pau
• Is Part Of: Expert review of clinical pharmacology. Volume 16:Issue 2(2023)
• Page Start: 133
• Page End: 148
• Publication Date: 2023-02-01
• Subjects: FLT3 inhibitors -- drug-drug interactions -- midostaurin -- gilteritinib -- quizartinib -- sorafenib -- ponatinib -- crenolanib; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2023.2174523
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: FLT3 inhibitors (FLT3i) are drugs in which there is limited experience and not yet enough information on the mechanisms of absorption, transport, and elimination; but especially on the potential drug-drug interactions (DDIs). There are therefore risks in the management of FLT3i DDIs (i.e. sorafenib, ponatinib, crenolanib, midostaurin, quizartinib, and gilteritinib) and ignoring them can compromise therapeutic success in acute myeloid leukemia (AML) treatment, in complex patients and secondary pathologies. Areas covered: This review summarizes the DDIs of FLT3i with P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting (OAT), organic cationic transporting (OCT), cytochrome P450 (CYP) subunits, and other minor metabolic/transport pathways. EMBASE, PubMed, the Cochrane Central Register and the Web of Science were searched. The last literature search was performed on the 14 February 2022. Expert opinion: FLT3i will be combined with other therapeutic agents (supportive care, doublet, or triplet therapy) and in different clinical settings, which means a greater chance of controlling and even eradicating the disease effectively, but also an increased risk to patients due to potential DDIs. Healthcare professionals should be aware of the potential interactions that may occur and be vigilant in monitoring those patients who are receiving any potentially interacting drug.